Literature DB >> 3861228

Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor.

P Picci, G Bacci, M Campanacci, M Gasparini, S Pilotti, S Cerasoli, F Bertoni, A Guerra, R Capanna, U Albisinni.   

Abstract

The predominant sites of viable and nonviable tumor were determined in the primary lesions of 50 patients with osteosarcoma after initial treatment with preoperative chemotherapy. The degree of tumor destruction was classified as good, fair, and poor and a map of the sites revealing viable and nonviable tumor was constructed. The study revealed several preferential sites where viable tumor was likely to persist: soft tissues, cortex, subcortex, ligaments, and areas in contact with cartilage (growth plate and/or articular cartilage). Localized areas of hemorrhage and necrosis, designated "lacunae," were noted within the tumor. They were frequently surrounded by bundles of viable tumor and appeared to correlate with open surgical biopsies. Factors responsible for this phenomenon and the persistence of viable tumor are discussed. The findings have important implications in the design of surgical treatment and in the use of needle biopsies to determine the effects of preoperative treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3861228     DOI: 10.1002/1097-0142(19851001)56:7<1515::aid-cncr2820560707>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

1.  Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.

Authors:  Hyung Jun Im; Tae Sung Kim; Seog-Yun Park; Hye Sook Min; June Hyuk Kim; Hyun Guy Kang; Seung Eun Park; Mi Mi Kwon; Jong Hyung Yoon; Hyeon Jin Park; Seok-ki Kim; Byung-Kiu Park
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-28       Impact factor: 9.236

2.  Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.

Authors:  K Junker; M Thomas; K Schulmann; F Klinke; U Bosse; K M Müller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis.

Authors:  Jyoti Bajpai; Shivanand Gamnagatti; Rakesh Kumar; Vishnubhatla Sreenivas; Mehar Chand Sharma; Shah Alam Khan; Shishir Rastogi; Arun Malhotra; Rajni Safaya; Sameer Bakhshi
Journal:  Pediatr Radiol       Date:  2010-10-27

4.  Degeneration of Paget's disease into sarcoma: clinical and therapeutic influencing factors.

Authors:  Alessandro Zati; Teresa Wanda Bilotta
Journal:  Chir Organi Mov       Date:  2008-04-12

5.  Local growth and the prognosis of osteosarcoma.

Authors:  P Wuisman; W F Enneking; A Roesner
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

6.  18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Authors:  Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong
Journal:  Skeletal Radiol       Date:  2011-02-06       Impact factor: 2.199

7.  Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Authors:  Vincent Crenn; Kevin Biteau; Jérôme Amiaud; Clotilde Dumars; Romain Guiho; Luciano Vidal; Louis-Romée Le Nail; Dominique Heymann; Anne Moreau; François Gouin; Françoise Redini
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

8.  Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents.

Authors:  Cristina Meazza; Roberto Luksch; Primo Daolio; Marta Podda; Alessandro Luzzati; Alessandro Gronchi; Antonina Parafioriti; Lorenza Gandola; Paola Collini; Andrea Ferrari; Michela Casanova; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Veronica Biassoni; Elisabetta Schiavello; Emilia Pecori; Maura Massimino
Journal:  Med Oncol       Date:  2014-02-21       Impact factor: 3.064

9.  Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.

Authors:  Qiang Lu; Gang Lv; Andre Kim; Jong-Myung Ha; Suhkman Kim
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

10.  [Chemotherapy-induced changes in high grade central osteosarcomas-experiences gained through the assignment as reference-pathologists of the COSS-studies].

Authors:  M Werner; G Delling
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.